BRD2 and cancer: Remarkably though, cluster heterogeneity within the cancer cell population was less pronounced within the NAT-PDAC sample set (Supplementary Fig. S3E–S3G), suggesting that FOLFIRINOX-based treatment may promote a more transcriptionally homogenous phenotype in cancer cells.